TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology PAGE 32 (2024) Abstr 11219 Carlsson Petri KC, Antonescu IE, Gallais F, Brekkan A. ConferenceGeneticPharmacometricsPhase IITrial design and analysis Pharmetheus Affiliates Senior Director, MIDD Consultant Fanny Gallais See bio Senior Director, R&D Scientist Ari Brekkan See bio